13G Filing: Park West Asset Management and Eagle Pharmaceuticals Inc. (EGRX)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.  )*

Check the appropriate box to designate the
rule pursuant to which this Schedule 13G is filed:

[   ] Rule 13d-1(b)

[X] Rule 13d-1(c)

[   ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this
form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter
the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed”
for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities
of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

  *
Beneficial ownership percentage is based upon 15,169,241 shares of
common stock, $0.001 par value per share (“Common Stock”), of Eagle Pharmaceuticals, Inc., a Delaware corporation
(the “Company”), issued and outstanding as of August 2, 2017, based on information reported by the Company in its
Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2017. Park West Asset Management
LLC (“PWAM”) is the investment manager to Park West Investors Master Fund, Limited, a Cayman Islands exempted
company (“PWIMF”), and Park West Partners International, Limited, a Cayman Islands exempted company
(“PWPI” and, collectively with PWIMF, the “PW Funds”), and Peter S. Park (“Mr. Park” and,
collectively with PWAM, the “Reporting Persons”) is the sole member and manager of PWAM. As of August 14, 2017,
PWIMF held 697,739 shares of Common Stock and PWPI held 88,681 shares of Common Stock. As a result of the foregoing, for
purposes of Reg. Section 240.13d-3, the Reporting Persons may be deemed to beneficially own the 786,420 shares of Common
Stock held in the aggregate by the PW Funds, or approximately 5.2% of the shares of Common Stock deemed to be issued and
outstanding as of August 14, 2017.

 * Beneficial
ownership percentage is based upon 15,169,241 shares of common stock,
$0.001 par value per share (“Common Stock”), of Eagle Pharmaceuticals, Inc., a Delaware corporation (the “Company”),
issued and outstanding as of August 2, 2017, based on information reported by the Company in its Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission on August 9, 2017. Park West Asset Management LLC (“PWAM”) is the
investment manager to Park West Investors Master Fund, Limited, a Cayman Islands exempted company (“PWIMF”), and Park
West Partners International, Limited, a Cayman Islands exempted company (“PWPI” and, collectively with PWIMF, the
“PW Funds”), and Peter S. Park (“Mr. Park” and, collectively with PWAM, the “Reporting Persons”)
is the sole member and manager of PWAM. As of August 14, 2017, PWIMF held 697,739 shares of Common Stock and PWPI held 88,681
shares of Common Stock. As a result of the foregoing, for purposes of Reg. Section 240.13d-3, the Reporting Persons may be deemed
to beneficially own the 786,420 shares of Common Stock held in the aggregate by the PW Funds, or approximately 5.2% of the shares
of Common Stock deemed to be issued and outstanding as of August 14, 2017.

* This Schedule 13G is being jointly filed by (i) PWAM, a Delaware limited liability company and the investment
manager to (a) PWIMF, a Cayman Islands exempted company that is the holder of 697,739 shares of Common Stock, as reported on this
Schedule 13G, and (b) PWPI, a Cayman Islands exempted company that is the holder of 88,681 shares of Common Stock, as reported
on this Schedule 13G; and (ii) Mr. Park, as the sole member and manager of PWAM.

The 786,420 shares of Common Stock held in the aggregate by the PW Funds, which constitute approximately 5.2%
of the shares of Common Stock deemed to be outstanding as of August 14, 2017, may be deemed to be beneficially owned (x) indirectly
by PWAM, as the investment adviser to PWIMF and PWPI, and (y) indirectly by Mr. Park, as the sole member and manager of PWAM. The
foregoing beneficial ownership percentage is based upon 15,169,241 shares of Common Stock issued and outstanding as of August 2,
2017, based on information reported by the Company in its Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2017.

SIGNATURE

          After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth
in this statement is true, complete and correct.

Attention: Intentional misstatements or omissions
of fact constitute

Federal criminal violations (See 18 U.S.C.
1001)

Exhibit Index

Exhibit A

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named
below agree to the joint filing on behalf of them of a statement on Schedule 13G (including amendments thereto) with respect to
the shares of common stock, $0.001 par value per share, of Eagle Pharmaceuticals, Inc., a Delaware corporation, and further agree
that this Joint Filing Agreement be included as Exhibit A to such Schedule 13G. In evidence thereof, the undersigned hereby execute
this agreement this 24th day of August, 2017.